SETD2 and renal carcinoma: Dysregulated sphingolipid metabolism, increasingly recognized as a chemoresistance mechanism, was exemplified by Rao et al. [54], who demonstrated that SETD2 loss enhances SM biosynthesis, promoting renal cancer progression.